Volume | 68,760 |
|
|||||
News | - | ||||||
Day High | 10.35 | Low High |
|||||
Day Low | 9.77 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Pulse Biosciences Inc | PLSE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.30 | 9.77 | 10.35 | 9.80 | 10.31 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,461 | 68,760 | $ 10.00 | $ 687,686 | - | 2.36 - 13.62 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:52:02 | formt | 100 | $ 9.72 | USD |
Pulse Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
538.92M | 54.99M | - | 700k | -58.51M | -1.06 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Pulse Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PLSE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 10.02 | 11.6398 | 9.7601 | 10.57 | 189,463 | -0.30 | -2.99% |
1 Month | 9.25 | 11.6398 | 8.67 | 9.98 | 163,793 | 0.47 | 5.08% |
3 Months | 12.60 | 13.35 | 7.77 | 9.68 | 196,695 | -2.88 | -22.86% |
6 Months | 4.70 | 13.62 | 3.78 | 8.67 | 218,112 | 5.02 | 106.81% |
1 Year | 2.98 | 13.62 | 2.36 | 7.66 | 193,333 | 6.74 | 226.17% |
3 Years | 25.68 | 29.16 | 1.18 | 7.52 | 150,498 | -15.96 | -62.15% |
5 Years | 17.72 | 45.82 | 1.18 | 9.87 | 125,299 | -8.00 | -45.15% |
Pulse Biosciences Description
Pulse Biosciences Inc is a medical therapy company that pursues the commercial introduction of its proprietary CellFX System utilizing its patent-protected Nano-Pulse Stimulation (NPS) platform technology. Through its proprietary CellFX System, the company can deliver a cell-focused effect on dysfunctional cells while preserving surrounding non-cellular tissue, a combination that may potentially lead to both improved efficacy and less collateral tissue damage. Substantial revenue is generated from North America Majorly due to the sale of systems. |